Interferon inhibitory activity in patients with multiple sclerosis

Archives of Neurology

Volumn 63, Issue 11, 2006, Pages 1579-1584

  Chadha, Kailash ^a   Weinstock Guttman, Bianca ^b   Zivadinov, Robert ^b   Bhasi, Kavitha ^d   Muhitch, Jason ^a   Feichter, Joan ^b   Tamaño Blanco, Miriam ^d   Abdelrahman, Nadir ^b   Ambrus Sr , Julian ^c   Munschauer, Frederick ^b   Ramanathan, Murali ^b,d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA 2 MICROGLOBULIN; BETA INTERFERON RECEPTOR; BETA1A INTERFERON;

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION;

ADULT; ANTIBODIES; BETA 2-MICROGLOBULIN; CASE-CONTROL STUDIES; CELL LINE; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, INTERFERON;

EID: 33751003501     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.11.1579     Document Type: Article

References (24)

1. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 1997;49:862-869.
2. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003;61:184-189.
3. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-1191.
4. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361:545-552.
5. Ambrus JL, Ambrus JL Jr, Chadha KC. Interferon inhibition in lupus erythematosus. N Engl J Med. 1988;319:582-583.
6. Ambrus JL, Ambrus JL Jr, Chadha S, et al. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol. 1997;96:255-265.
7. Ambrus JL Sr, Dembinski W, Ambrus JL Jr, et al. Free interferon-alpha/ beta receptors in the circulation of patients with adenocarcinoma. Cancer. 2003;98:2730-2733.
8. Ikossi-O'Connor MG, Ambrus JL, West T, Lillie MA, Milgrom H, Chadha KC. Interferon and interferon inactivators in patients with acquired immune deficiency syndrome and Kaposi's sarcoma: a preliminary report. Res Commun Chem Pathol Pharmacol. 1984;45:271-277.
9. Ikossi-O'Connor MG, Chadha KC. The effect of malignant epithelial tumors, surgical therapy, and bacterial sepsis upon various parameters of interferon system. J Surg Oncol. 1984;26:27-34.
10. Chadha KC, Ambrus JL, Halpern J, et al. The interferon system in carcinoma of the cervix: effect of radiation and chemotherapy. Cancer. 1991;67:87-90.
11. Ambrus JL, Chadha KC, Ambrus JL Jr. Interferon inhibitors. Ann Intern Med. 1991;114:606-607.
12. Ikossi-O'Connor MG, Chadha KC, Lillie MA, Bernstein Z, Zucker-Franklin D, Ambrus JL. Interferon inactivator(s) in patients with AIDS and AIDS-unrelated Kaposi's sarcoma. Am J Med. 1986;81:783-785.
13. Attallah A, Lee JB, Ambrus JL, Ambrus CM, Karakousis C, Takita H. Prostaglandin E2 production by human tumors: defense mechanism against the host? a preliminary report. Res Commun Chem Pathol Pharmacol. 1984;43:195-201.
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
15. Finter NB. Standardization of assay of interferons. Methods Enzymol. 1981;78(pt A):14-22.
16. Chadha KC, Ambrus JL, Stadler I, Ambrus JL Jr. Interferon inhibitor in the blood of patients with systemic lupus erythematosus. J Biol Regul Homeost Agents. 1991;5:1-9.
17. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170:1409-1414.
18. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology. 2003;61:1444-1446.
19. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001;57:1239-1247.
20. Zivadinov R, Dwyer M, Watt KL. Measurement of cerebral grey and white matter atrophy measurement from various MRI pulse sequences using different segmentation algorithms [abstract]. J Neurol. 2004;251(suppl 3):S89.
21. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004;56:548-555.
22. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000;20:857-866.
23. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783-793.
24. Medenica RD, Mukerjee S, Huschart T, Corbitt W. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis. J Clin Apher. 1994;9:216-221.